Negma Group has transformed 120 convertible bonds in Oxurion leading to a EUR 300,000 capital enhance. This is a component of Negma Group’s EUR 30 million Capital Commitment1 that can enable Oxurion to focus on progressing its novel and differentiated again of the eye drug candidate focusing on potential market alternatives of over USD 5 billion.
Leuven, BELGIUM, Boston, MA, US – November 4, 2022 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of main participations in issuers of which shares are admitted to buying and selling on a regulated market and relating to miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), pronounces the under data, following the issuance of 15,000,000 new peculiar shares on November 2, 2022, for a complete quantity of EUR 300,000, as the consequence of the conversion of 120 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital enhance by way of the conversion of the convertible bonds, the complete quantity of shares issued by Oxurion quantities to 92,825,765 excellent peculiar shares carrying voting rights (in comparison with 77,825,765 excellent peculiar shares beforehand). This quantity might be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following up to date data:
| 72,656,161.32 | |
|
92,825,765 |
|
92,825,765 |
|
|
|
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical firm creating subsequent era customary of care ophthalmic therapies, that are designed to enhance and higher protect imaginative and prescient in sufferers with retinal issues together with diabetic macular edema (DME), the main trigger of imaginative and prescient loss in working-age individuals, in addition to different circumstances. Oxurion intends to play an essential function in the therapy of retinal issues, together with the profitable growth of THR-149, its novel therapeutic for the therapy of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a possible new customary of take care of the as much as 50% of DME sufferers displaying suboptimal response to anti-VEGF remedy. Oxurion is headquartered in Leuven, Belgium, with company operations in Boston, MA. More data is out there at www.oxurion.com.
Important details about forward-looking statements
Certain statements on this press launch could also be thought of “forward-looking”. Such forward-looking statements are based mostly on present expectations, and, accordingly, entail and are influenced by varied dangers and uncertainties. The Company due to this fact can not present any assurance that such forward-looking statements will materialize and doesn’t assume any obligation to replace or revise any forward-looking assertion, whether or not because of this of new data, future occasions, or another cause. Additional data regarding dangers and uncertainties affecting the business and different components that might trigger precise outcomes to vary materially from any forward-looking assertion is contained in the Company’s Annual Report. This press launch doesn’t represent a suggestion or invitation for the sale or buy of securities or belongings of Oxurion in any jurisdiction. No securities of Oxurion could also be provided or bought inside the United States with out registration beneath the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any relevant U.S. state securities legal guidelines.
For additional data please contact:
1 Press launch Oxurion, 06/04/2021 and Press launch Oxurion, 02/09/2022
- OXUR PR_Voting rights (ENG)_20221104
